Meros Investment Management LP Increases Holdings in CryoPort, Inc. $CYRX

Meros Investment Management LP increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 13.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 626,427 shares of the company’s stock after buying an additional 76,687 shares during the quarter. CryoPort comprises 2.4% of Meros Investment Management LP’s holdings, making the stock its 19th largest position. Meros Investment Management LP’s holdings in CryoPort were worth $6,014,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. LPL Financial LLC lifted its position in CryoPort by 6.6% during the fourth quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock worth $224,000 after buying an additional 1,433 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in CryoPort by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after buying an additional 1,557 shares in the last quarter. State of Wyoming lifted its position in CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after buying an additional 3,301 shares in the last quarter. Basepoint Wealth LLC purchased a new position in CryoPort during the fourth quarter worth approximately $34,000. Finally, BNP Paribas Financial Markets increased its stake in CryoPort by 55.2% during the third quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after acquiring an additional 4,225 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Insider Activity

In related news, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the completion of the transaction, the insider directly owned 109,719 shares of the company’s stock, valued at $1,587,633.93. The trade was a 23.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 23,214 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the transaction, the director directly owned 67,894 shares of the company’s stock, valued at $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 232,970 shares of company stock valued at $3,666,107. 10.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Guggenheim raised their target price on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Needham & Company LLC raised their target price on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Craig Hallum raised their target price on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Finally, BTIG Research raised their target price on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, CryoPort currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.11.

CryoPort Trading Up 1.4%

Shares of NASDAQ CYRX opened at $14.83 on Tuesday. CryoPort, Inc. has a twelve month low of $6.16 and a twelve month high of $16.73. The stock has a fifty day simple moving average of $12.54 and a 200-day simple moving average of $10.38. The stock has a market capitalization of $747.43 million, a PE ratio of 10.99 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. On average, equities analysts predict that CryoPort, Inc. will post -0.85 earnings per share for the current year.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.